
NGM Biopharmaceuticals: Eye Disorder Data Due 2nd Half Of 2022 (NASDAQ:NGM)
metamorworks/iStock via Getty Images NGM Biopharmaceuticals (NASDAQ:NGM) is a great speculative biotech play to look into. That’s because in the 2nd half of 2022 there is a major catalyst that is approaching. This will be […]